After Long Wait, Zytiga To Boost J&J’s China Oncology Presence
This article was originally published in PharmAsia News
Previously a symbol of China's drug lag problems, Zytiga is finally available to increasing numbers of prostate cancer patients in the country, seven months after J&J's local pharmaceutical subsidiary Xian Janssen obtained a regulatory nod from the China FDA. But without initial reimbursement coverage, J&J is depending on patient assistance programs to expand drug access.
Register for our free email digests: